Interpretation of EQA results and EQA-based trouble shooting by Gunn Berit Berge Kristensen & Piet Meijer
©Copyright by Croatian Society of Medical Biochemistry and Laboratory Medicine. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License 
(http://creativecommons.org/licenses/by-nc-nd/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
http://doi.org/10.11613/BM.2017.007 Biochemia Medica 2017;27(1):49–62 
  49
Abstract
Important objectives of External Quality Assessment (EQA) are to detect analytical errors and make corrective actions. The aim of this paper is to des-
cribe knowledge required to interpret EQA results and present a structured approach on how to handle deviating EQA results. The value of EQA and 
how the EQA result should be interpreted depends on five key points: the control material, the target value, the number of replicates, the acceptance 
limits and between lot variations in reagents used in measurement procedures. This will also affect the process of finding the sources of errors when 
they appear. The ideal EQA sample has two important properties: it behaves as a native patient sample in all methods (is commutable) and has a 
target value established with a reference method. If either of these two criteria is not entirely fulfilled, results not related to the performance of the 
laboratory may arise.  To help and guide the laboratories in handling a deviating EQA result, the Norwegian Clinical Chemistry EQA Program (NKK) 
has developed a flowchart with additional comments that could be used by the laboratories e.g. in their quality system, to document action against 
deviations in EQA. This EQA-based trouble-shooting tool has been developed further in cooperation with the External quality Control for Assays and 
Tests (ECAT) Foundation. This flowchart will become available in a public domain, i.e. the website of the European organisation for External Quality 
Assurance Providers in Laboratory Medicine (EQALM).
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Introduction
The scope of External Quality Assessment (EQA) in 
laboratory medicine has evolved considerably 
since Belk and Sunderman performed the first 
EQA scheme in the late 1940’s (1). Today, EQA 
schemes are an essential component of a labora-
tory’s quality management system, and in many 
countries, EQA is a component of laboratory ac-
creditation requirements (2,3). EQA should verify 
on a recurring basis that laboratory results con-
form to expectations for the quality required for 
patient care.
A typical EQA scheme (EQAS) consists of the fol-
lowing events: A set of samples is received by the 
laboratory from an external EQA organization for 
measurements of one or more components pre-
sent in the samples. The laboratories do not know 
the concentration of the components in the sam-
ples and perform measurements in the same man-
ner as for patient samples. The results are returned 
to the EQA organizer for evaluation and after some 
time the laboratory receive a report stating the de-
viation of their results relative to a “true” value (as-
signed value). Reports may also include evaluation 
of whether the individual laboratory’s results met 
the analytical performance specifications and an 
evaluation of the performance of the various meas-
urement procedures used by the participants.
Important objectives of EQA are, beside monitoring 
and documenting the analytical quality, to identify 
poor performance, detect analytical errors, and 
make corrective actions. Participation in EQA gives 
an evaluation of the performance of the individual 
laboratory and of the different methods and instru-
ments (3,4). Therefore, proper and timely evaluation 
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of EQA survey reports are essential and even a must 
for accreditation (see ISO 15189, paragraph 5.6.3.4). 
In this opinion paper, we focus on the knowledge 
required to interpret an EQA result and present a 
structured approach on how to handle an EQA er-
ror. The paper is limited to EQA for evaluation of 
quantitative measurement procedures.
Knowledge required to interpret EQA 
results 
The value of participating in EQAS for the labora-
tory depends on proper evaluation and interpreta-
tion of the EQA result. Key factors for interpreting 
EQA results are knowledge of the EQA material 
used, the process used for target value assignment, 
the number of replicate measurement of the EQA 
sample, the range chosen for acceptable values 
around the target (acceptance limits), and the im-
pact of between lot variations in reagents used in 
measurement procedures (4-6). 
EQA material
The most important property of the EQA sample is 
commutability (7-9). The significance of this is 
something that one has become more and more 
aware of in recent years. A commutable EQA sam-
ple behaves as a native patient sample and has the 
same numeric relationship between measure-
ments procedures as is observed for a panel of pa-
tient samples. A non-commutable EQA sample in-
cludes matrix related bias that occurs only in the 
EQA sample but not in authentic clinical patient 
samples and therefore, does not give meaningful 
information about method differences. Matrix re-
lated bias is due to an unwanted distortion of the 
test result attributed to physical and chemical dif-
ferences in the samples, compared to the patient 
material the measurement procedures are direct-
ed towards. In a recently published article con-
cerning method differences for immunoassay’s, 
non-commutability for EQA materials was ob-
served on 13 out of 50 occasions (5 components, 5 
methods and 2 EQA samples) (9). The bias demon-
strated by the EQA samples was five times found 
to be in an opposite direction compared with the 
native serum samples. Therefore, EQA materials 
should be tested for commutability and if evalua-
tion of method differences is intended, it is man-
datory. Additionally, the sample should be stable 
during the survey period, homogeneous, available 
in sufficient volume and have clinical relevant con-
centrations (10,11). Higher concentrations of com-
ponents can be achieved by adding components 
(spiking) to pooled unaltered samples but this 
may induce non-commutability (12,13). In practice, 
the EQA sample very often is a compromise be-
tween ideal behaviour in accordance with native 
samples and stability of the material and there-
fore, may not be commutable, which limited the 
opportunities in EQA result evaluation (4). 
Assignment of target values
If the EQA sample is commutable, target value as-
signment could be made by using a reference 
measurement procedure or a high-specificity 
comparative method that is traceable to a refer-
ence measurement procedure (14,15). In this case, 
all participants are compared to the same assigned 
value and trueness can be assessed. Target assign-
ment by value transfer based on results from certi-
fied reference materials is possible if the commut-
ability of the reference materials has been verified 
(16-18). An example is Labquality’s EQAS 2050 Se-
rum B and C (2-level) that use transferred values 
from NFKK Reference Serum X (Ref. NORIP home 
site (http://nyenga.net/norip/index.htm) – Tracea-
bility), as assigned values for 16 components. Se-
rum X has certified values from IMEP 17 Material or 
Reference Serum CAL (19). For many components, 
a reference method or certified reference material 
is not available. In that case, an overall mean or 
median can be used as the assigned value, after 
removal of outliers or by the use of robust statisti-
cal methods (20). All measurement procedures are 
expected to give the same results for a commuta-
ble sample. That gives the possibility to compare 
the result with other methods. However, the meas-
urement procedure with most participants will 
have greatest influence on the overall mean or 
median, and you do not know what the true value 
is. An alternative is to use the mean (or median) of 
the peer-group (see below) means (or medians) in 
order to give the same weight to each peer-group 
(21). A common reference assigned value should 
not be used if the commutability of the EQA sam-
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ple is unknown because it is not possible to deter-
mine if a deviation from the assigned value is due 
to matrix-related bias, calibration bias or that the 
laboratory did not confirm to the manufacturer’s 
recommended operation procedure.  
The most common procedure used to assign a tar-
get value if the commutability of the EQA sample 
is unknown is to categorize participant methods 
into peer-groups that represent similar technolo-
gy and calculate mean or median of the peer-
group, after removal of outlier values, and use this 
as the assigned value. A peer-group consist of 
methods expected to have the same matrix-relat-
ed bias for the EQA sample and it is possible to as-
sess quality, i.e. verifying that a laboratory is using 
a measurement procedure in conformance to the 
manufacturer’s specification and to other labora-
tories using the same method. A limitation is the 
number of participants in each group. The uncer-
tainty of the calculated assigned value would be 
larger in a peer group with few participants com-
pared to a group with many participants. The vari-
ability of results in the group will also influence the 
uncertainty of the assigned value. A high variabili-
ty combined with few participants will give the 
greatest uncertainty of the assigned value.
Acceptance limits
To assess if the EQA result is acceptable, accept-
ance limits (i.e. analytical performance specifica-
tions) around the target value must be established 
(22-24). The acceptance limits can be considered 
regulatory, statistical or clinical.
Regulatory limits have the intention to identify 
laboratories with sufficiently poor performance 
that they should not be able to continue to prac-
tice. These limits tend to be wide and are often 
based on “fixed state-of-the-art”. The German 
RiliBÄK and the USA Clinical Laboratory Improve-
ment Amendments (CLIA) have defined such regu-
latory limits (25,26).
Statistical limits are based on “state-of-the-art” 
and the assumption that the measurement proce-
dures is acceptable if it is in concordance with oth-
er using the same method. The assessment of the 
individual laboratory is given as z-scores, which is 
the number of standard deviations (SD) from the 
assigned value the EQA result. Assessment of z-
scores is based on the following criteria: - 2.0 ≤ z ≤ 
2.0 is regarded as satisfactory; - 3.0 < z < - 2.0 or 2.0 
< z < 3.0 is regarded as questionable (‘warning sig-
nal’); z ≤ - 3.0 or z ≥ 3.0 is regarded as unsatisfac-
tory (‘action signal’). These criteria is stated in ISO/
IEC standard 17043:2010 (27). The performance of 
the individual laboratory is compared against the 
dispersion of results obtained by the participants 
in the peer-group in each survey. A disadvantage 
is that these limits are variable and may change 
with time as methods and instruments evolve. An-
other disadvantage with statistical based criteria is 
that the limits may vary between peer-groups 
measuring the same component. Imprecise-meth-
od peer groups will have a large acceptance inter-
val whereas precise-method peer groups will have 
a small interval for acceptable results, independ-
ent of what is required for clinical needs. Several 
EQA organizations use z-scores in the feedback re-
ports to the participants.
Clinical limits can be based on a difference that 
might affect clinical decisions in a specific clinical 
situation (28). These limits are desirable but may 
be difficult to implement because very few clinical 
decisions are based solemnly on one particular 
test. More common are clinically established limits 
derived from biological variation in general (29,30). 
A challenge is the fact that the existing database 
on biological variation is based on few studies or 
studies with rather poor quality. However, in the 
strategic conference to arrive at a consensus on 
how to define analytical performance goals that 
took place in Milan 2014, a working group for re-
vising the current biological variation database 
was established (31-33).
Both regulatory and clinical limits are fixed limits 
and the uncertainty of the assigned value will be a 
fraction of the acceptance interval. To account for 
the uncertainty of the definitive value, Norwegian 
Quality Improvement of Laboratory Examinations 
(Noklus) have added a fixed interval around the 
target value in their acceptance limits (34). When 
the acceptance interval is expressed as a percent, 
it might also be necessary to include a fixed unit 
interval below a concentration at which a percent 
is not reasonably achievable because the concen-
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tration-independent variability of a measurement 
procedure becomes a larger fraction of the accept-
ance interval.
Replicate measurements
EQA results are meant to reflect results of patient 
samples and in most of the schemes, the partici-
pant is asked to perform a single measurement of 
the EQA sample. The acceptance limits are often 
given in %, and are established according to a To-
tal Error allowable (TEa) concept (35,36). Total error 
is assessed because bias, imprecision, and analyti-
cal non-specificity can contribute to variation in a 
single result. If replicate measurements of the sam-
ples are included, it may be appropriate to have 
different limits to separately assess bias and im-
precision. 
Between lot variation
Between lot variation in the reagents used in 
measurement procedures may influence partici-
pant assessment in EQA (5,37). The percentage of 
participants with a “poor” quality assessment de-
clined from 38% if using a common target value to 
10 and 4% when using a method specific target 
value and a lot specific target value, respectively 
(5). Between lot variation has been described in 
several publications for glucose strips (38-41). Ide-
ally, the use of lot-specific target values in EQAS 
would allow assessment of the individual partici-
pant’s performance, but such assessments are not 
feasible in routine EQAS due to the larger number 
of lots on the market. EQA organizers should, how-
ever, register lot numbers when relevant and in 
some instances comment on lot variation in feed-
back reports (37). Additionally, between lot varia-
tion found when using control materials may not 
mirror results when using native blood (5,37). To 
evaluate the clinical importance of between lot 
variation discovered in routine EQAS, the actual lot 
should therefore be examined using native blood. 
A structured approach for handling 
unacceptable EQA results
An unacceptable EQA result should be investigat-
ed by the participant (the person in charge of EQA 
in the laboratory) to find the cause of the devia-
tion and make corrective actions. According to ISO 
15189, an accredited laboratory shall participate in 
EQAS, monitor and document EQA results, and im-
plement corrective actions when predetermined 
performance criteria are not fulfilled (3). In spite of 
the extensive use of EQAS in evaluating the quality 
of the analytical work done in medical laborato-
ries, it is remarkable that there is little aid in the 
process of finding the sources of errors when they 
appear. Therefore, the Norwegian Clinical Chemis-
try EQA Program (NKK) has developed a tool for 
handling deviating EQA results. 
All the mentioned key factors that must be taken 
into consideration when interpreting an EQA re-
sult also apply for handling an EQA error. The ideal 
EQA sample has two important properties; it be-
haves as a native patient sample toward all meth-
ods (is commutable) and has an assigned value es-
tablished with a reference method with small un-
certainty. If either of these two criteria are not en-
tirely fulfilled, results with errors NOT related to 
the quality of the laboratory may arise. Therefore, 
the EQA provider should take steps in the scheme 
design to avoid or ameliorate adverse conse-
quences. This could be done for example, by using 
peer-group assigned values for a non-commuta-
ble material. It is important to distinguish between 
different types of error (external, generating cost 
without benefit) and those important ones that 
are caused by the laboratory itself (internal). For 
the laboratory, errors caused by themselves are 
most important and of their primary interest. How-
ever, errors made by either manufacturers and/or 
EQA organizers (external) may also affect the qual-
ity of laboratory performance and therefore could 
have a major impact.
A simple relation has to be fulfilled if a deviation is 
to be further investigated:
|R – AV| > L
where R is the laboratory result, AV is the assigned 
value and L is the maximum acceptable deviation, 
i.e. acceptance limits. Many EQA organizers have 
suggested acceptance limits for their EQAS. The 
laboratories should be aware of these limits, and 
in countries where participating in EQAS is not 
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mandatory/regulatory, it is the laboratories re-
sponsibility to define which limits is relevant for 
their use. In reports from EQA organizers, the labo-
ratory’s performance history is often shown graph-
ically together with the EQA organizer’s accept-
ance limits. Of the three variables in the above 
equation, only one, R, is the immediate responsi-
bility of the laboratory. Errors in AV has an external 
source while an error in L is fundamentally internal 
as commented above even if most laboratories 
tend to adopt the limits proposed by the EQA or-
ganizer. To understand the complexity of finding 
the cause of an EQA error all sources of deviation 
in an EQA result are included in a flowchart and 
have to be considered. In those EQAS using the z-
scores as an individual performance index R 
should be within the range - 2 ≤ z-score ≤ 2. This 
indicate that the laboratory result is within the 
95% range of the distribution of all results. Results 
with a z-score < - 3 or > 3 can be identified as un-
satisfactory, while results with a z-score between - 
3 and -2 or 2 and 3 are questionable (a warning 
signal). This means the laboratory should investi-
gate whether there is a reason why the results 
tend to become an outlier.
The history of developing a flowchart 
In 2008 and 2009, the topic for group works at 
NKK’s annual meetings was “How to handle a devi-
ating EQA result”. The result of this work was fur-
ther processed by the NKK expert group and re-
sulted in a flow chart with additional comments 
that could be used by the laboratories, e.g. in their 
quality system, to document actions against devi-
ations in EQA.
In 2012-2013 NKK carried out a follow-up and an 
evaluation of the flowchart. Deviating EQA results 
from Labquality’s EQA scheme 2050 Serum B and 
C (2-level), survey 4 and 6, 2012) were selected and 
the laboratories were asked to use the flowchart to 
assess the EQA error and state the cause of the er-
ror. They were also asked if they use the flowchart 
regularly, and if not, why they do not use it. Finally, 
they were asked if they have any suggestions for 
improvement of the flowchart. Fifty-six percent of 
the invited laboratories replied (39/69). The results 
showed that most errors (81%) were the laborato-
ry’s responsibility (internal causes), 15% the EQA 
provider’s responsibility (external causes), whereas 
4% were a mix (internal/external causes). The most 
common errors were transcription errors (72%) 
both with respect to internal and external causes. 
For 4% of the deviating EQA results the partici-
pants did not reach any conclusion. Fifty-eight 
percent of the laboratories that responded used 
the flowchart regularly. Of these, 37% commented 
that they found the flowchart comprehensive and 
a bit complicated, but very useful in training/edu-
cational situations. They suggest changing the or-
der of the items in the flowchart and start with 
transcription errors, the most common cause to a 
deviating EQA result (unpublished data). 
The recommendations from the evaluation has 
been taken into account and a new version of the 
flowchart has been developed in cooperation with 
the External quality Control for Assays and Tests 
(ECAT) Foundation in the Netherlands (Figure 1). 
The content of the original flowchart is kept and 
where necessary expanded and re-structured. 
Description of the flowchart
The flowchart starts with the most frequently er-
rors followed by the logical steps in the flow of an 
EQA survey (from pre-survey issues to report and 
interpretation – see Figure 1). Four different as-
pects elucidate each item in the flowchart: Obser-
vation – what is the potential error, Responsibili-
ty – who is responsible for the error, Comment – a 
short comment on action to undertake, Note – a 
more detailed description of actions (see Figure 2). 
The responsible could be the participant, the EQA-
provider (EQAP), and/or the manufacturer, each 
marked with different colour. 
Before starting evaluating the potential cause for a 
deviating result, the report and/or comment letter 
should be read carefully for a possible explanation 
for deviating results. If no explanation is given, the 
flowchart should be used (Figure 1 and Figure 2) 
to reveal the potential cause(s). 
The flowchart starts with the most probable caus-
es of error; “Transcription errors” (item 1-6). The 
EQA provider may wrongly enter the data or the 
laboratory may record or report a wrong result. In 
the evaluation of the first version of the flowchart, 
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Version 10-10-2016  Page 1 of 2 
Error in recording test results 
from the instrument 
Participant Review process of test result recording 1 
Participant Error in reporting test results to EQA organisation Review process of result reporting 2 
Participant Mixing-up test results Review process of result recording / reporting 3 
Participant Report results with wrong 
units 
Report results in the correct (standard) units of the 
method 4 
Participant 
Report the wrong method 
and/or equipment Report the correct method and/or equipment used 5 
EQAP Error in data entry by EQA 
provider 





The EQA provider distributed 
by accident an inappropriate 
sample 
An inappropriate selection of sample materials may 




Because of this error you may have tested wrong or 




Error in packaging the samples You may have not received the correct samples 9 
Sample(s) probably not send in a proper way which 
may have affected the quality of the EQA samples 10 
Participant 
EQAP Problem with sample stability Insufficient sample stability may affect your performance assessment. Claim for explanation 11 
EQAP Problem with sample homogeneity 
In-homogeneity of sample(s) may affect your 
performance assessment. Claim for explanation 12 
EQAP Error in the instruction letter of EQA provider 
Because of an error in the instruction letter you may 






Participant Problems with the receipt of 
the samples 
Samples were sent to the wrong person or 
department 
14 
Participant Inappropriate storage of the 
samples till use 
Samples were not  stored according to the 
instructions 15 
Participant Problems with the 
reconstitution of the samples Samples were not reconstituted in a proper way 
16 
Participant 
The instructions were not 
followed properly by the 
participant 
Inappropriate handling of the samples 17 
Sam
ple receipt/handling 
Error in sample labelling 



















FLOWCHART FOR HANDLING DEVIATING EQA RESULTS 
 
Introduction 
Before you start evaluating the potential cause for a deviating result, please read carefully the report and/or comment letter for a 
possible explanation for deviating results (see pre-note). If no explanation is given please use the flowchart below to reveal the 





No.  Observation  Responsibility  Comment  Note 
Figure 1. Flowchart for handling deviating EQA results.
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Version 10-10-2016  Page 2 of 2 
Change in the instructions of 
the manufacturer Participant 
Review the most recent test procedure of the 
manufacturer 18 
Was there a problem with the 
equipment 
Review the operation status of the equipment at the 
time the EQA samples were measured 
19 
Was there a problem with the 
reagents 
 
Review the quality of the reagents used 20 
Was there a problem with the 
test performance 
 
Review all aspects of the test performance 21 
Was there a problem with the 
internal quality control 
samples 
Review the internal quality control results at the time 





The statistical procedure used 
is probably not appropriate 
for the distribution of test 
results and/or the group size 
Review if the statistical procedure used is appropriate 
for the evaluation of this data set 
23 
EQAP Evaluate whether the EQA provider had used the proper manner for establishment of the AV  24 
EQAP Error in presentation of 
results 
Inform EQA provider about error and claim for 
amended report 25 
Deviation in accordance with 
previous EQA results 
Review whether the deviation is caused by an internal 
or external source. 26 
Large variation in EQA results 
for the method used 
Review whether the deviation is caused by inappro-
priate sample material and/or the method itself. 27 
Deviation is systematic for all 
EQA samples 
Review whether the deviation is caused by an internal 
or external source. 28 
Report and Interpretation 
Manufacturer 
Data Handling EQA Provider 
 
Error in establishment of 
assigned value (AV) 
Repeated analysis showed 
similar deviation 
Review whether the deviation is caused by an internal 
or external source. 29 
Source for the deviation is 
unknown 
No clear explanation for the deviation could be revealed. 
When the error persist is future EQA surveys a new cause 


















Participant Manufacturer EQAP 
Manufacturer EQAP 
Participant Manufacturer EQAP 
Participant Manufacturer EQAP 
 
No.  Observation  Responsibility  Comment  Note 
Figure 1. Flowchart for handling deviating EQA results (continued).
transcriptional errors were the most common 
cause for a deviating result. 
The next is “Pre-survey issues” (item 7-13). Obvious-
ly, a lot may go wrong before the sample reaches 
the laboratory like sample selection, inappropriate 
stability or homogeneity, a mistake in labelling or 
an error i  packaging. These errors are the EQA or-
ganizer’s responsibility and should have been 
commented on in the comment letter (see above). 
Unfortunately, this is often not the case even 
though these errors are hard, and often impossi-
ble, to detect for the laboratory. Examples of more 
subtle origin are related to the stability of the sam-
ples. A good procedure is always to store the EQA 
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The comment letter or comment section in the report may include comments regarding remarkable observations 
(e.g. a relative large deviation for a specific method mean with respect to the overall assigned value). Evaluate 
carefully the remarks and consider whether this could be explaining your deviating result. 
1 
The participant had made an error in recording the test result of the EQA sample(s) and as such reported a wrong 
result(s). This is an internal cause for the error made. The participant should carefully review the process of result 
recording and take appropriate action to avoid this problem in future surveys.   
2 
The participant had made an error in reporting the test result of the EQA sample(s) to the EQA organisation. This is an 
internal cause for the error made. The participant should carefully review the process of result reporting and take 
appropriate action to avoid this problem in future surveys.   
3 
The participant had mixed-up the test results either at the level of recording the test result from the instrument or 
when the test results were reported to the EQA organisation. The participant should carefully review the process of 
result recording and/or reporting and take appropriate action to avoid this problem in future surveys. 
4 
The participant had reported the result with the wrong unit (e.g. report the result in U/dL instead of U/mL). This may 
lead to incorrect treatment of the data in the evaluation software of the EQA organiser. In this case the result could 
be assigned as an outlier. The participant should select the correct unit when reporting a result to avoid this problem 
in future surveys. 
5 
The participant had reported the wrong method and/or equipment used. This may lead to inclusion of the result in 
the wrong method/equipment group. This may affect both the total evaluation of that group(s) as well as the 
evaluation of your own result and performance assessment. The participant should select the correct 
method/equipment when reporting a result to avoid this problem in future surveys. 
6 The EQA provider had wrongly entered your data (e.g. result, unit, method, instrument etc.) into the database which leads to a wrong evaluation of your performance. Please inform the EQA provider and ask for an amended report.  
7 
The EQA provider had distributed inappropriate sample material (e.g. the sample material is not commutable for your 
specific method. I.e. the sample material used by the EQA provider behave for your specific method not identical as a 
real patient sample). This may affect your performance assessment. It is the responsibility of the EQA provider to 
write a note about this issues in the report or comment letter. If this is not done, please inform the EQA provider and 
ask for an amended report or comment letter. 
8 
The EQA provider had made a mistake in the labelling of the sample(s). As such the evaluation is not in 
correspondence with the description of the sample information and/or expected target values. It is the responsibility 
of the EQA provider to write a note about this issue in the report or comment letter. If this is not done, please inform 
the EQA provider and ask for an amended report or comment letter. In addition, the EQA provider should provide 
replacement of the sample to give you the opportunity to rerun the sample or the EQA provider has to rerun the 
whole survey. 
9 
You have received wrong samples because of an error in the packaging by the EQA provider.  Because you were not 
aware of this fact you had measured the wrong samples which may had affect your performance assessment. It is the 
responsibility of the EQA provider to write a note about this issues in the report or comment letter. If this is not done, 
please inform the EQA provider and ask for new samples and an amended report. 
It is also the responsibility of the participant to check whether they have received the correct samples as soon as 
possible after receipt. If this is not done by the participant it is also the responsibility of the participant if incorrectly 
received samples are still measured. 
10 
The EQA provider selected an inappropriate manner to distribute the sample (e.g. inappropriate packaging material, 
distribution at an inappropriate time period, etc.). This may lead to delay in the receipt, damage of the package etc. 
Measuring such samples may have affected your performance assessment. Please inform the EQA provider in time 
about such issues in future surveys. In addition, the EQA provider should provide replacement of the sample(s) to 
give you the opportunity to rerun the sample and provide you with an amended report. In general, inform the EQA 
provider immediately after the delayed receipt of samples or when the package is damaged and sample are probably 
affected and ask for replacement of the sample(s). 
11 
The EQA provider had distributed a sample with insufficient stability. This may affect your performance assessment.  
It is the responsibility of the EQA provider to write a note about this issue in the report or comment letter and rerun 
the survey. If this is not done, please inform the EQA provider and ask to rerun the survey with better samples and 
provide the participants with an amended report. 
12 The EQA provider had distributed a sample with insufficient homogeneity. This may affect your performance assessment. It is the responsibility of the EQA provider to write a note about this issue in the report or comment 
Figure 2. Notes to flowchart for handling deviating EQA results
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letter. If this is not done, please inform the EQA provider and ask for an amended report or comment letter. In 
addition, the EQA provider should provide replacement of the sample(s) to give you the opportunity to rerun the 
sample and provide you with an amended report. 
13 
The EQA provider had provided inappropriate information in the instruction letter. Because of this you may have not 
handled the sample in an appropriate way. This may have affected your performance assessment. It is the 
responsibility of the EQA provider to write a note about this issues in the report or comment letter. If this is not done, 
please inform the EQA provider and ask for an amended report or comment letter. In addition, the EQA provider 
should provide replacement of the sample(s) to give you the opportunity to rerun the sample and provide you with 
an amended report. 
14 
The participant is informed by the EQA provider about the dispatch date of the samples (e.g. by an annual survey 
schedule). There is a delay in the delivery of the samples in your laboratory. This may be caused for instance by wrong 
information available by the EQA provider about the address details or wrong distribution within the hospital. This 
may lead to bad test results. Please evaluate carefully the delivery and/or distribution of the samples and take 
appropriate action to avoid this problem in future surveys. If there is a systematic delay in the delivery of the sample 
(e.g. because of the post services in for in your particular country), the EQA provider should be informed and another 
way of delivery of the samples should be used (e.g. courier service). 
15 
Samples were not stored in a proper way after receipt. For instance, they were not put into the refrigerator. This may 
lead to bad test results. Please evaluate carefully the procedure for storage of the samples and take appropriate 
action to avoid this problem in future surveys.   
16 
The samples were not reconstituted in a proper way because, for instance, you did not use calibrated pipettes. 
Therefore, you pipette the wrong volume. Another possibility is that you did not mix the sample properly. This may 
lead to bad test results. Please evaluate carefully the procedure for reconstitution of the samples and take 
appropriate action to avoid this problem in future surveys.   
17 
You have not read the instruction letter carefully. Therefore, you may have made a mistake in the handling of the 
sample (for example: the sample used in this survey was stable for a shorter time period as usual and you did not 
notice this. Therefore, you did not measure the sample within the stable time period).  This may lead to bad test 
results. Please read carefully the instruction letter every time. 
18 
If the manufacturer has made changes in the test constitution and/or procedure they should have made the user 
aware of this. If this is not done the manufacturer should be informed and asked for improved communication in 
future cases. The laboratory should evaluate/validate the revised test procedure and adapt the test procedure when 
necessary. 
If the laboratory has not changed the test procedure based on information given by the manufacturer, internal 
actions have to be carried out.   
19 
If there was any problem related to the equipment at the time the EQA samples were measured, (e.g. problems due 
to maintenance issues, calibration, test settings) internal actions have to be carried out to prevent repeated 
problems.   
20 
If there was any problem related to the reagents used at the time the EQA samples were measured, (e.g. problems 
with a specific lot. no., reconstitution, storage) actions have to be carried out to prevent repeated problems. If the 
problem is caused by external factors the distributor or manufacturer of the reagents should be contacted.   
21 If there was any problem related to the performance of the test at the time the EQA samples were measured, (e.g. test settings, local modifications, calibration) internal actions have to be carried out to prevent repeated problems.  
22 
If the results of the internal quality control samples could explain the deviation of the EQA results, internal actions 
have to be carried out to prevent repeated problems. Make sure that the patient results were correct during the 
period the EQA samples were measured. Look for trends in internal quality control results. 
23 
It is the responsibility of the EQA provider to provide the participant with information about the statistical procedure 
used (e.g. information included in each report or provided on an annual basis in a survey manual). Review whether 
there was maybe a problem with the statistical method used for this particular data set, e.g. due to a non-normal 
distribution of the results or the size of the data set. Contact the EQA provider and ask for further explanation by the 
EQA provider.  
24 
If the assigned value (AV) was established by a reference method the deviation might be caused by either the 
assignment of the AV or your method. Check the deviation of other methods used. If the deviation is similar to your 
method the AV might be incorrect. Inform the EQA provider. If the deviation is not similar to other methods, analyse 
reference material and some patient samples in parallel with another reliable method. Make the manufacturer of 
your method aware of the deviation. Ask for appropriate action. 
If the AV is a consensus value (calculated from all the results in a method group consisting of different methods) and 
the deviation is representative for your method, realise that the AV of the total group is not representative for your 
method. The laboratory should evaluate their EQA results to the method specific consensus value and not to the AV 
of the total group. If the method specific AV is not given in the report, ask the EQA provider for possibilities to provide 
Figure 2. Notes to flowchart for handling deviating EQA results (continued).
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If the AV is calculated from a small number of results this might result in a less reliable AV. Interpret the result 
carefully. 
If the AV is not calculated from original results but from a mix of original and modified results (e.g. by the use of a 
local correction factor), this might contribute to a large variation and an incorrect AV. When reporting results, it 
should be possible to mark if the results are not original and as such should be excluded from the assignment of the 
AV or treated as a separate method group (in the case sufficient participants use the same modification of results).  
25 The EQA provider had probably wrongly presented the results in the report (e.g. results for your specific method are linked to another method.). Please inform the EQA provider and ask for an amended report.  
26 
A similar deviation has been observed earlier. If the deviation is typical for the method the cause is external [see 
notes 18 (e.g. change in method) and 20 (e.g. problem with specific lot of reagents)]. The cause can also be due to the 
EQA samples used (e.g. non-commutable for a particular method). If not, the cause is internal. Make sure that the 
internal quality control and patient results were correct at the time the EQA samples were measured. Undertake 
appropriate corrective actions. 
27 
If relevant, complain the EQA organiser that the sample material used in the survey was probably inappropriate for 
your method. Some materials show especially large variation for one specific method and in that case the deviation 
might be large compared to your acceptable limits without being large compared to the variation for your method. 
Inform EQA organiser and ask for the use better commutable material (when possible).  
28 
When multiple samples with different concentration were used, investigate thoroughly if a systematic error is 
present. A systematic error may have different sources, e.g. problems with the calibrator (external), pipetting error 
(internal), problems with a certain lot no of the reagents used (external), problem with the value assignment 
(external). The potential cause should be investigated thoroughly and appropriate actions should be undertaken.  
29 
Repeat analysis on stored EQA material. If the repeat analysis shows no deviation anymore the method seems to be 
OK.  Make sure that the internal quality control and patient results were correct at the time the EQA samples were 
measured. When necessary undertake appropriate corrective actions. 
If repeat analysis shows the same deviation, ask the EQA organiser for a repeat sample(s) for re-analysis. If the repeat 
analysis shows no deviation anymore the method seems to be OK. There was most likely something wrong with the 
EQA sample (e.g. wrong sample sent by EQA organiser, pipetting error during reconstitution). If repeat analysis show 
the same deviation there seems to be, for instance, something wrong with the method used (external cause) or with 
the sample sent by the EQA organiser (external cause). Investigate thoroughly potential causes and undertake 
appropriate actions.  
 
Figure 2. Notes to flowchart for handling deviating EQA results (continued).
sample at stable conditions at least until the re-
port is received – a reanalysis of the sample may 
eliminate many sources of error. If you do not have 
any sample material left, you should ask the EQA 
organizer for a new sample. 
The next section, “Sample receipt/handling” (item 
14-17), is solely the laboratory’s responsibility.  The 
laboratory should carefully check that the EQA 
provider has the correct address details and that 
all instructions for handling the sample from the 
EQA organizer, has been followed. The visual ap-
pearance of the specimen should be checked by 
reception for an immediate check of sample quali-
ty and physical integrity and also that the sample 
identifiers match the documentation.
“Test Performance” (item 18-22) is next. The labora-
tory or the instrument or kit manufacturer is re-
sponsible for errors in this section. Local docu-
mentation of measurement is important: who/
when/how. You may locally have changed the pro-
cedure of measurement (e.g. factorized results: in-
ternal source) or the producer of the method may 
have changed the calibrator/reagents/procedure 
(external) without informing you (example creati-
nine, ALP). The problem may be related to the 
equipment, the reagents or the test performance. 
Is the problem new to your laboratory or is it an 
old problem? Have the error occurred before? It is 
important to evaluate results in relation to previ-
ous surveys. In other words, evaluation of the re-
sults of a single survey may be insufficient to re-
veal the cause of the problem.  If it is new, look at 
your internal quality control data (IQC). First, look 
for systematic deviations (bias/trends) that may 
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explain the EQA result. If this is the cause of the er-
ror, are your IQC rules not stringent enough or is L 
too narrow? In any case, is there a need for reanal-
ysis of any of the patient samples in the relevant 
analytical run? If no hints can be found in IQC, you 
should proceed in the flowchart.
Errors in “Data handling” (item 23-25) are external 
and usually, not the responsibility of the laborato-
ry. The problem could be related to the statistical 
procedure used in handling the data, e.g. para-
metric methods used when the data are not nor-
mally distributed, the consensus value is based on 
few participants causing a large deviation, or it 
may stem from uncertainty caused by a mix of fac-
torized and original results. The establishment of 
the assigned value (AV) is a challenge. All partici-
pants, regardless of instrument or method, should 
be evaluated against the AV established by a refer-
ence method when this is available and commut-
able material is used. A deviation that is represent-
ative for one particular instrument or method is 
caused either by the EQA provider (non-commuta-
ble material) or the instrument or method used 
(e.g. a problem with a certain lot of reagents). An 
evaluation based on a reference value for a non-
commutable EQA sample is a mistake by the EQA 
provider. Another example applies to a deviation 
between a particular instrument or method and 
the peer-group AV, based on results from a large 
number of instruments or methods. The deviation 
is similar for all participants with the particular in-
strument or method, and in that case, the instru-
ment or method is linked to the wrong peer-
group. It is important to check that the grouping 
of the instrument or method is correct, by both 
the EQA provider and the participant. This is a fre-
quent cause of error unless the method is stated 
and adjusted at each survey. One should also be 
aware of that in a peer-group consisting of several 
instruments or methods the instrument or meth-
od with most participants will have a greater influ-
ence on the assigned value. Errors in this section 
may be difficult for the participant to detect and 
should have been commented on in the feedback 
report. 
The last section is “Report and Interpretation” (item 
26-29). Is the deviation clinically important? If not, 
the acceptable limits should be reconsidered, and 
may be expanded. Limits expressed in percent are 
probably not suitable for the lowest concentra-
tions of the component because the measure-
ment uncertainty may be larger than the accept-
ance limits if the concentration is low. Especially 
high concentrations are often less interesting and 
therefore also the deviation. However, from an an-
alytical point of view it might still be worth reduc-
ing the error. This does not apply to limits based 
on state-of-the-art. A deviation in accordance with 
previous results has probably been handled earli-
er. The error may be the responsibility of the par-
ticipants, the EQA provider or the manufacturer. 
The mean of all results for one particular method, 
however, may always be used to distinguish be-
tween errors general for the method (external) 
and errors in the laboratory (internal), even if you 
do not know the commutability of the sample. It 
may be that the error is already recognized as a 
general problem or specific for your method. An 
unusually large variation for a particular method 
may be caused by poor EQA material (external/
EQA provider) or between lot variation in reagents 
for that specific method and several lots present 
(external/manufacturer). It could also be due to 
change in the method by the manufacturer. A sus-
pected internal error requires review of the inter-
nal quality control (IQC) and the patient results in 
the period where the EQA sample was analysed. 
A similar deviation observed in several samples 
with different concentrations, may suggest that a 
systematic error is present. In that case, it may be 
wise to check previously EQA results to look for a 
trend. For more details, look closer to Figure 1 and 
Figure 2.
Sometimes there is no explanation to the EQA er-
ror. It may have been a transient error in the sys-
tem at the time of measurement. The error should 
be followed up in later EQA surveys.  
It should be realised that an error made by the 
EQA provider or manufacturer may cause a deviat-
ing result for a participant in an EQAS. The partici-
pant should therefore also consider this possibility 
when evaluating deviating EQA results. Errors 
caused by the EQA provider’s should have been 
commented in the comment letter. These errors 
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are often hard and sometimes impossible for the 
participant to discover and handle. In order to im-
prove their schemes, the EQA provider should cre-
ate a checklist based on this flowchart as a tool in 
their work to make ongoing EQA schemes more 
useful for the participant.
Limitations
The flowchart presented in this paper is limited to 
cover mistakes that occur in the analytical phase 
of the total testing process. Transcription errors, 
which counted for about three quarters of the mis-
takes or errors, could be classified as post-analyti-
cal errors, i.e. not part of the analytical process, 
and therefore may “falsely” affect the evaluation 
of the analytical performance. Today, writing down 
the patient results are not part of the daily routine 
when laboratories are highly automatized. The 
fact that a laboratory professional does not check 
written results, might reflect lack of attention to 
deliver correct results and hence, indicate a lack of 
quality. Another limitation is the limited use of the 
flowchart so far. 
Future directions
The flowchart itemizes the steps taken by many 
EQA providers when working with participants to 
understand and correct adverse performance and 
is used in the format of Corrective and Preventa-
tive Action (CAPA) documentation or Root Cause 
Analysis (RCA) tools. The flowchart is a useful addi-
tion to these as it summarizes these processes for 
participants. To our knowledge, this is the first 
time such a structured approach on how to handle 
deviating EQA results, have been published. So far, 
the flowchart has had a very limited use. However, 
the flowchart will soon become available in the 
public domain, i.e. the website of the European or-
ganisation for External Quality Assurance Provid-
ers in Laboratory Medicine – EQALM. This flow-
chart can be the basis for modified versions for 
specific EQA areas and be further improved based 
on the experience of users.  
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